RAC - Charts & Price Action, page-15833

Here are some of the upcoming events that could generate news for Race Oncology shareholders:

• Release of top-line results from Phase 2 clinical trials of Zantrene for the treatment of breast cancer: This is the most important event that could generate news for Race Oncology shareholders. If the results are positive, it could help the company to secure partnerships and collaborations to accelerate the development and commercialization of Zantrene. The results could also help to increase investor interest in Race Oncology, which could lead to higher share prices.
• Initiation of Phase 2 clinical trials of Zantrene for the treatment of metastatic colorectal cancer: This is another important event that could generate news for Race Oncology shareholders. If the results of these trials are positive, it could help Race Oncology to expand its pipeline of drug candidates and to reach a new patient population.
• Announcement of new partnerships and collaborations: Race Oncology has been actively seeking partnerships with other companies in the pharmaceutical industry. The company is expected to announce several new partnerships in the near future. These partnerships could help Race Oncology to accelerate the development and commercialization of its drug candidates.

Overall, Race Oncology is a clinical-stage oncology company with a promising pipeline of drug candidates. The company is expected to release several important updates in the second half of 2023, and it is likely to remain in the news in the coming months.